Pharmacological inhibition of SRPK1 in triple negative breast cancer cell lines results in a reduced capacity for invasion and migration, supporting a link between SRPK1 and LIMK2 signalling in the context of metastatic spread in triple negative breast cancer [51]. The gene discussed is LIMK2; the disease is triple-negative breast carcinoma.